Benznidazole biotransformation and multiple targets in <i>Trypanosoma</i> cruzi revealed by metabolomics by Trochine, Andrea et al.
  
 
 
Trochine, Andrea, Creek, Darren J., Faral-Tello, Paula, Barrett, Michael P., 
and Robello, Carlos (2014) Benznidazole biotransformation and multiple 
targets in Trypanosoma cruzi revealed by metabolomics. PLoS Neglected 
Tropical Diseases, 8 (5). e2844. ISSN 1935-2727 
 
Copyright © 2014 The Authors 
 
 
 
http://eprints.gla.ac.uk/95238/ 
 
 
 
 
Deposited on: 23 July 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Benznidazole Biotransformation and Multiple Targets in
Trypanosoma cruzi Revealed by Metabolomics
Andrea Trochine1¤a*, Darren J. Creek2,3¤b, Paula Faral-Tello1, Michael P. Barrett2, Carlos Robello1,4*
1Unidad de Biologı´a Molecular, Institut Pasteur de Montevideo, Montevideo, Uruguay, 2 The Wellcome Trust Centre for Molecular Parasitology, Institute for Infection,
Immunity and Inflammation and Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 3Department of
Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria, Australia, 4Departamento de
Bioquı´mica, Facultad de Medicina, Universidad de la Repu´blica, Montevideo, Uruguay
Abstract
Background: The first line treatment for Chagas disease, a neglected tropical disease caused by the protozoan parasite
Trypanosoma cruzi, involves administration of benznidazole (Bzn). Bzn is a 2-nitroimidazole pro-drug which requires
nitroreduction to become active, although its mode of action is not fully understood. In the present work we used a non-
targeted MS-based metabolomics approach to study the metabolic response of T. cruzi to Bzn.
Methodology/Principal findings: Parasites treated with Bzn were minimally altered compared to untreated trypanosomes,
although the redox active thiols trypanothione, homotrypanothione and cysteine were significantly diminished in
abundance post-treatment. In addition, multiple Bzn-derived metabolites were detected after treatment. These metabolites
included reduction products, fragments and covalent adducts of reduced Bzn linked to each of the major low molecular
weight thiols: trypanothione, glutathione, c-glutamylcysteine, glutathionylspermidine, cysteine and ovothiol A. Bzn
products known to be generated in vitro by the unusual trypanosomal nitroreductase, TcNTRI, were found within the
parasites, but low molecular weight adducts of glyoxal, a proposed toxic end-product of NTRI Bzn metabolism, were not
detected.
Conclusions/significance: Our data is indicative of a major role of the thiol binding capacity of Bzn reduction products in
the mechanism of Bzn toxicity against T. cruzi.
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Introduction
Ten million people worldwide are infected with Trypanosoma
cruzi, the causative agent of Chagas disease, and 40 million are at
risk of infection [1,2]. In spite of a substantial reduction in
prevalence over the last few decades, the disease is considered
among the world’s 17 most neglected tropical diseases and is
responsible for 13,000 annual deaths according to the World
Health Organization (WHO). T. cruzi is naturally transmitted to
humans and other mammals by reduviid insects of the subfamily
Triatominae, and may also be transmitted by blood transfusions,
organ transplants, orally through contaminated food, and verti-
cally from mother to child. The disease progresses with an initial
acute phase, usually asymptomatic, that can subsequently develop
into a chronic form with cardiac and digestive pathologies that can
lead to death [3].
Benznidazole (Bzn), formerly commercialized as Rochagan and
Radanil (Roche), and nifurtimox (Nfx), marketed as Lampit
(Bayer), are the only drugs proven effective against Chagas disease.
Both contain a nitro group linked, respectively, to an imidazole or
furan ring, and unwanted side effects are common, leading to
treatment discontinuation in some cases. Bzn has the best safety
and efficacy profile, and is therefore used as first line treatment. A
major limitation is the low potency of these drugs against parasites
in the established chronic disease, which is the form most
commonly encountered clinically [4,5]. The therapeutic benefit
of Bzn in established mild to moderate Chagas disease is currently
under scrutiny in the Benznidazole Evaluation for Interrupting
Trypanosomiasis (BENEFIT) trial [6]. In spite of the limitations of
Bzn and Nfx in treatment, only a few compounds are undergoing
clinical trials against chronic Chagas disease, and there are no
immediate prospects of a vaccine. Interest in nitro-heterocyclic
compounds has recently been reinvigorated given the advance-
ment of several members of the class into clinical trials [7,8,9].
Bzn was discovered as an anti-trypanosomal agent through
screening against parasites without understanding its mechanism
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of action. Other nitroimidazoles, including the 5-nitroimidazole
metronidazole, are well-established in the treatment of anaerobic
protozoal and bacterial infections [10]. The mode of action of
nitroheterocyclic compounds appears to involve metabolic activa-
tion of the compounds initiated through reduction of the
compounds’ nitro group. Subsequent metabolism of the com-
pounds can be divergent. The anti-mycobacterial agent PA-824,
for example, is reduced by a deazaflavin (F420)-dependent
nitroreductase (Ddn) in M. tuberculosis and eventually decomposes
to various reactive nitrogen species including nitric oxide [11]. Bzn
activity has been proposed to be mediated via reduced interme-
diates that covalently modify macromolecules in vivo, including
lipids, DNA and proteins, rather than by formation of radical
intermediates producing reactive oxygen species [12,13]. An
unusual prokaryotic type I nitroreductase (NTRI) was identified
in trypanosomatid protozoa which is primarily responsible for the
reductive activation of some trypanocidal nitroheterocycles
including Bzn, Nfx and also fexinidazole [14,15,16]. In vitro
TcNTR can catalyse the consecutive two electron reduction of
Bzn, leading to formation of a dihydroxy-dihydroimidazole
derivative which may decompose to give glyoxal, a well-known
toxic metabolite. Glyoxal was postulated to contribute to the
pleiotropic effects of Bzn on trypanosomes [17], although roles for
each of the metabolic products of Bzn have not been investigated
in situ. Here we report, for the first time, an untargeted
metabolomics analysis of T. cruzi to investigate changes in the
parasite associated with exposure to the drug. Using a platform
involving HILIC chromatography to separate low molecular
weight metabolites coupled to high resolution mass spectrometry
[18] we detected in the order of a thousand T. cruzi metabolites
and were able to identify metabolic perturbations associated with
Bzn exposure, as well as the production of Bzn metabolites and
their in situ reaction products.
Methods
Parasite growth and metabolite extraction
T. cruzi epimastigotes of the DM28c strain [19] were grown in
LIT medium supplemented with yeast extract and 10% foetal
bovine serum at 28uC [20]. For metabolite extraction a protocol
was adapted from that used for other trypanosomatid protozoa
[18,21]. Cultures were initiated by inoculating exponentially
growing epimastigotes to a final concentration of 2.56107
parasites per mL. Two days after inoculation, parasites were
counted in a Neubauer chamber and 16108 parasites per sample
were taken for treatment (approximately 1 mL). After adding 20
or 50 mM Bzn, parasites were incubated at 28uC for 6 h. Tubes
containing parasites in suspension were quenched on ice for
3 min, after which Bzn was added to control cells when necessary
(Table S1). Cells were collected immediately by centrifugation
(20006g, 4uC, 3 min). Supernatants were carefully removed from
cell pellets. Samples from each supernatant were separated for
analysis as medium samples (5 mL). Cell disruption and metabolite
extraction was performed using 200 ml chloroform/methanol/
water 20/60/20 (v/v/v) during 1 hour in a Thermomixer
(1000 rpm, 4uC –Eppendorf AG, Hamburg, Germany). Metab-
olite extracts were separated from cell debris by centrifugation
(13,0006 g, 4uC, 3 min). Extracts were stored at 270uC under
nitrogen gas until analysis. Biological replicates were grown,
incubated and extracted on different days. A short drug incubation
period was chosen to impede changes in the number of parasites
during treatment. For viability determinations, treated parasites
were washed, incubated in fresh medium for 72 h and counted in
Neubauer chamber.
Mass spectrometry
Samples were analysed on an Exactive Orbitrap mass
spectrometer (Thermo Fisher Scientific) in both positive and
negative modes (rapid switching), coupled to a HPLC separation
with a ZIC-HILIC column (Sequant) as has previously been
described [18]. All samples from each experiment were analysed in
the same analytical batch in randomised order and the quality of
chromatography and signal reproducibility were checked by
analysis of quality control samples, internal standards and total
ion chromatograms. A standard mix containing approximately
160 authentic metabolite standards was run at the start of each
analysis batch to aid metabolite identification.
MSMS analysis was performed on an LTQ Orbitrap Velos
mass spectrometer (Thermo Fisher Scientific) in positive mode
with ZIC-HILIC chromatography as described above. High
resolution (15,000) MSMS spectra were obtained with HCD
induced fragmentation at normalised collision energy of 35 eV.
MSMS spectra for the follow-up 50 mM Bzn experiment were
collected at unit resolution.
Data processing
Untargeted metabolite analysis was conducted with the freely
available software packages mzMatch [22] and Ideom (http://
mzmatch.sourceforge.net/ideom.php) [23]. Raw LC-MS data was
converted to mzXML format and peak detection was performed
with XCMS [24] and saved in peakML format. Mzmatch.R was
used for sample alignment, peak filtering (based on reproducibility,
peak shape and an intensity threshold of 3000), gap filling and
annotation of related peaks. Ideom was used to remove
contaminants and LC-MS artefact peaks and to perform
metabolite identification. Metabolite identities were confirmed
by exact mass (within 3 ppm after correction for loss or gain of a
proton in negative mode or positive mode ESI respectively) and
retention time where authentic standards were available for
analysis. Putative identification of all other metabolites was made
on the basis of exact mass and predicted retention time from all
metabolites from the KEGG, MetaCyc and Lipidmaps databases
[18]. The m/z values corrected for proton gain or loss are referred
as m/zc in the text. In cases where identification was putative, the
Author Summary
The unicellular parasite Trypanosoma cruzi infects humans,
leading to Chagas disease, endemic in Central and South
America and responsible for 13,000 annual deaths. Only
two drugs have proven effective against Chagas, nifurti-
mox and benznidazole (Bzn). Bzn has the best safety and
efficacy profiles and is thus used as first line treatment. Bzn
is a pro-drug, and possesses a nitro group which needs to
be enzymatically reduced within the parasite to become
active. We have investigated for the first time, by means of
mass spectrometry based metabolomics, the global
changes to small metabolites that occur once Bzn enters
the parasite. A decrease in the levels of several thiols,
including cysteine and trypanothione, and an increase in
gamma-glutamyl containing dipeptides were observed
after treatment. Reduced metabolites of Bzn were also
detected, together with numerous covalent conjugates of
the drug combined with low molecular weight thiols and
some non-thiol metabolites. Overall, Bzn treatment pri-
marily affects thiol containing molecules in T. cruzi, and
this interference with thiol metabolism contributes to the
drug’s mode of action.
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most likely metabolite was chosen based on available chemical and
biological knowledge [23]. However, LC-MS data alone is often
insufficient for accurate isomer identification and lists of alterna-
tive identifications with meta-data for each identified formula are
accessible in the macro-enabled Ideom files (Files S1 and S2; help
documentation available at mzmatch.sourceforge.net/ideom.php).
Quantification is based on raw peak heights, and expressed
relative to the average peak height observed in untreated cells from
the same experiment. Unidentified peaks in the LC-MS data were
also investigated for drug-induced changes. After removal of LC-
MS artefacts and known contaminants, measured exact masses
were compared with theoretical exact masses of Bzn derived
metabolites contained in Bznmet database (‘‘targeted sheet’’, Files
S1 and S2). This database included reported and putative Bzn
reduction products and covalent adducts of Bzn with small cellular
metabolites, all retrieved from existing reports on in vivo and in vitro
modification processes for Bzn and similar nitroimidazoles, covering
enzymatic and non-enzymatic conversions [17,25,26,27]. Accurate
mass and relative isotope abundance was used to determine the
chemical formulae for the remaining unidentified metabolites
detected specifically in the 50 mM Bzn treated samples. In most
cases these formulae contain the subset C12H14N4O, suggesting
that they are adducts of reduced Bzn with a broad range of
unexpected metabolites. In addition, a targeted analysis of
potential metabolites in the Bznmet database was performed on
the raw data using accurate mass within a 3 ppm mass range,
to allow detection of metabolites that may have been excluded
by the automated data processing due to peak shape, intensity
or reproducibility filters. Manually retrieved intensity and RT
values from all samples are included in File S3.
Accession numbers
TcNTRI: GenBank AHD24669.1
TbNTRI: GenBank AAX69576.1
Dnd Mycobacterium tuberculosis: UniProtKB/Swiss-Prot P71854.1
TcCPR-B: GenBank ABI15738.1
TcOYE: GenBank AAX54861.1
TcAKR: GenBank ACD93222.1
Results
General description of the Trypanosoma cruzi
metabolome
Metabolites were extracted from T. cruzi epimastigote cell pellets
with a monophasic solvent mixture of chloroform, methanol and
water (1:3:1); separated and analysed by ZIC-HILIC chromatog-
raphy coupled to high accuracy MS using an Orbitrap mass
spectrometer. Five biological replicates were analysed for each
condition. Signal extraction and initial filtering of the LC-MS data
yielded 3,117 peaks for negative mode and 5,528 peaks for positive
ESI mode. Additional artefact filtering and polarity merging in
Ideom reduced the list of features to 1,477 candidate molecules, of
which over 70% (1,069) matched compounds in the metabolite
databases based on accurate mass and retention time information
[18]. A complete list of putatively identified metabolites, with the
detected peak heights for each sample and confidence values for
their identifications is supplied in File S1 (see ‘‘Comparison’’
sheet). Only putatively identified metabolites were considered for
intensity comparisons among groups of samples.
Based on the Ideom software’s automated metabolite calling we
can divide metabolites into several classes, although additional
confirmation of the identity of each individual metabolite would be
required to impose certainty on these classifications. The largest
class of metabolites was peptides, representing 42.1% of the total
metabolites (135 dipeptides, 183 tripeptides and 132 tetrapeptides)
(Figure 1 and File S1). The next largest class of metabolites was
amino acids and compounds associated with amino acid metab-
olism (amino acids, thiol compounds and polyamines), which
represented 14.6% of the total putatively identified metabolites.
In addition to peptides and amino acids, metabolites from a
diverse range of metabolic pathways were detected (Figure 2),
including lipid (110), carbohydrate (44), nucleotide (33) and
cofactor metabolism (26). Putatively identified metabolites that
lack KEGG [28] or Lipidmaps [29] pathway annotations were
classified as unmapped (210), among these there are N-acetylated
amino acids and polyamines, acyl-carnitines and acyl-glycines.
A hallmark metabolite in kinetoplastid parasites, including
trypanosomes, is trypanothione. This di-thiol is composed of two
Figure 1. Distribution of total metabolites identified in Trypanosoma cruzi epimastigote samples. The pie chart depicts the percentages
of putatively identified metabolites from each of the metabolite classes. A total of 1,069 metabolites were analysed.
doi:10.1371/journal.pntd.0002844.g001
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molecules of glutathione linked by one molecule of spermidine,
and it is usually detected as a multi charged ion by ESI-MS [30].
Under the conditions used in this study, the tri-charged form of
trypanothione disulphide was detected in all parasite samples with
very high S/N ratios. Furthermore, a mass consistent with tri-
charged homotrypanothione, a metabolite unique to T. cruzi [31],
was also detected although with eighty times lower signal intensity
than trypanothione. It is important to note that the protocol used
here leads to extensive oxidation of thiols, thus the relative
quantification of the intracellular redox state of these molecules is
not possible. Other common small thiols detected were glutathi-
one, cysteine/cystine and homocysteine. Detected polyamines
included cadaverine, spermidine, putrescine and some modified
forms such as N-acetylspermidine, N-acetylputrescine and gam-
ma-glutamylputrescine.
Metabolic profile of benznidazole treated Trypanosoma
cruzi
In an attempt to analyse the metabolic changes induced by Bzn
treatment, T. cruzi epimastigotes were exposed to 20 mM Bzn over
six hours (cBt samples) after which metabolites were extracted.
Approximately 80% of the parasites remained viable after this
treatment (not shown). Parasites that were not exposed to Bzn (cTc)
and parasites to which Bzn was added just prior to the extraction of
metabolites (cBc) (to control for any mass spectrometry related
effects due to drug) were included as controls. Medium samples
were analysed in parallel including fresh medium (Med) and spent
mediums collected from cBc (mBc) and cBt samples (mBt).
Principal Component Analysis (PCA) of the automatically
filtered data indicated that no obvious differences were found
among the different groups of cells samples (cBc, cBt and cTc),
although medium samples could be readily separated from cell
samples (Figure S1). This indicated that the global structure of the
T. cruzi metabolome was little changed by this treatment with Bzn.
Univariate analysis of individual metabolites using p,0.05 as a
significance threshold in t-tests and a fold abundance change above
1.4 revealed relatively few differences between treated and
untreated parasites (see ‘‘Comparison’’ sheet, File S1). Among
these, trypanothione disulphide, homotrypanothione disulphide
and cystine (cysteine disulphide) were significantly diminished in
abundance after treatment. Three glutamate containing di-peptides
were elevated in Bzn treated samples (Figure 3), and although they
were not structurally characterised, they likely represent the
gamma-glutamyl dipeptides involved in glutathione recycling.
In addition to the relatively small changes in the metabolites
discussed above, two metabolites which were substantially elevated
in treated cells over controls were identified through the
automated screening of the datasets. One metabolite (m/zc
278.14, RT 11.1) was assigned as N-Benzoyl-D-arginine and
another (m/zc 292.15, RT 10.2) as 4-coumaroyl-3-hydroxyagma-
tine, based on mass similarity. However, as discussed below, these
were mis-identifications of Bzn metabolites that have masses (i.e.
molecular formulae) identical to these representatives from the
IDEOM metabolite database.
Considering that Bzn acts as a pro-drug which undergoes
reductive metabolism to generate toxic intermediates [4,5,13], the
Figure 2. Putatively identified metabolites mapped onto the KEGG metabolic pathways. Coloured nodes (putatively identified
metabolites) demonstrate coverage of diverse metabolic pathways (grey lines indicate annotated T. cruzi pathways). Node colour represents
metabolite abundance in Bzn-treated T. cruzi relative to untreated controls on a continuous colour scale: blue: 0.5, yellow: 1 (no change), red: 2-fold
increase. Node size indicates P-value from unpaired Welch’s t-test: large: p,0.01, medium: p,0.05, small: P$0.05. The large blue spot in the lower-
right corner represents trypanothione disulphide (relative abundance= 0.7, P-value,0.01). Image generated with iPath2.0 [66].
doi:10.1371/journal.pntd.0002844.g002
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presence of unidentified peaks at significantly higher concentra-
tions in treated than in untreated cells prompted us to re-scan the
filtered data seeking putative molecules derived from in situ Bzn
metabolism. We applied a correlation analysis on the intensities of
all the LC-MS peaks, searching for molecules that were highly
correlated with the metabolites detected in treated samples (and
thus assumed to be derived from Bzn) and with low or no
abundance in all the other samples (control parasites, media and
solvent samples) (‘‘all Data’’ sheet, File S1). Six additional ions
corresponding to putative Bzn metabolites were found after
carefully removing additional MS artefacts derived from these
molecules (Table 1).
To further investigate the identity of the Bzn metabolites and to
search for additional Bzn metabolites, an in-house database of
reported and putative Bzn metabolites was built: Bznmet database
(‘‘Targeted’’ sheet, File S1). The theoretical m/zc values contained
in the database (109 ions belonging to 56 different molecules) were
compared with the accurate measured m/zc values from the
collected filtered data and also the raw data, resulting in
identification of a number of Bzn metabolites (Table 1 and File
S3). Finally, to gain additional information to support the
proposed metabolite structures, MSMS fragmentation spectra
were collected for the ions of interest (File S4).
Once the LC-MS data were examined, a number of reduced
derivatives of Bzn were found to be highly abundant in treated
samples. The signal at m/zc 264.12 (RT 13 min) was attributed to
a dihydroxy-dihydro derivative of Bzn: 2-(2-amino-4,5-dihydroxy-
4,5-dihydroimidazol-1-yl)-N-benzylacetamide (3). Additionally,
the two metabolites initially detected in Bzn-treated samples and
mis-identified, as N-Benzoyl-D-arginine (m/zc 278.13, RT
11.1 min) and 4-coumaroyl-3-hydroxyagmatine (m/zc 292.15,
RT 10.2 min), could be assigned as methoxy derivatives of the
Bzn dihydroxy-dihydro derivative (2, 6). Also, a molecule with an
m/z value expected for the hydroxylamine or some hydroxy
derivatives of Bzn was found (m/zc 246.11, RT 11 min) (11). N-
benzyl-2-guanidinoacetamide (m/zc 206.11, RT 11.7 min) (5) was
also detected. This molecule was reported to arise after the Bzn
dihydroxy-dihydro derivative decomposes, or reacts with other
molecules, to release glyoxal [17,32]. Nevertheless, glyoxal adducts
with nucleotides, nitrogenated bases or amino acids could not be
detected in our data. Also, 2-(2-amino-1H-imidazol-1-yl)-N-
benzylacetamide (m/zc 230.11, RT 10.85 min) (1), a six electron
reduction product of Bzn, was highly abundant in treated samples.
Multiple detected signals were assigned to covalent adducts of
Bzn reduction products with low molecular weight thiols. Three
signals were assigned to different Bzn-trypanothione adducts, all
detected as tri-charged ions (m/zc 322.47, RT 29.1; m/zc 316.46,
RT 28 and m/zc 356.8, RT 29.9 min) (10, 13, 16). Likewise, a
glutathionylspermidine adduct was detected as a tri-charged ion
(m/zc 220.78, RT 34.5 min) (15). The mono-charged ion with m/
zc 349.12 (RT 11 min) was assigned to a cysteine-containing
adduct (9). In addition, we found a glutathione adduct with
reduced Bzn, both as a mono and a di-charged ion, with m/zc
535.18 and 267.59 respectively. Each of these ions were detected
at two different retention times (RT 17.6 and 18.4 min), most
probably representing two isomers (7, 8). Ovothiol A covalent
adducts were assigned to signals present at two retention times on
HILIC chromatography (m/zc 429.16 and m/zc 214.58; both at
RT 19.5 and 21.5 min) (14, 12).
High quality MSMS spectra were obtained for a number of
putative Bzn-derived molecules, even though some metabolites
were detected with very low intensity signals. The analysis of the
fragmentation patterns is summarized in File S4. Although
additional structural data would be necessary to unequivocally
Figure 3. Metabolites displaying significant differences between control and 20 mM Bzn treated T. cruzi samples. Metabolites
displaying significant differences between control samples (cBc) and 20 mM Bzn treated samples (cBt) with p,0.05 (unpaired T-test) and fold change
.1.4. Bzn derived metabolites were not included.
doi:10.1371/journal.pntd.0002844.g003
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identify all the metabolites, the fragmentation data, together with
the high resolution accurate mass MS and RT data, are supportive
for the proposed structures. In this sense, all MSMS spectra
contained a fragment of m/zc 90.047 assigned to the benzene ring
moiety of Bzn and also present in the Bzn fragmentation pattern.
In addition, molecules proposed as related structures displayed
fragmentation patterns with shared peaks. Metabolites with m/zc
264.12 (3) and 278.13 (2) (hydroxy and methoxy derivatives)
included 14 shared signals, while cysteine (9) and glutathione
adducts (7, 8) (Bzn-thiol conjugates) displayed five shared peaks.
Furthermore, shared peaks were obtained when glutathione and
trypanothione MSMS fragmentation spectra were compared with
the corresponding spectra of the proposed Bzn-thiol adducts.
Among the common peaks we found the typical fragment
encountered in glutathione containing molecules of mass 129 Da
[33] and also fragment masses that correspond to the neutral loss
of pyroglutamic acid. Also, 34S isotopic peaks were observed for a
number of metabolites, confirming the presence of thiol moieties
in these covalent adducts (Table 1).
Finally, a group of cell-free control samples were analysed
separately: a control group in which the drug was incubated with
the growth medium was compared with the medium alone (not-
shown). In this analysis we observed that no Bzn metabolites arise
after the drug incubation with the medium components after
6 hours at 28uC. Thus, all of the observed Bzn derived metabolites
are produced by T. cruzi-mediated metabolism of the drug.
Additional Bzn derived metabolites are identified using a
higher concentration of drug
Since a number of the Bzn-related metabolites were found only
with very low abundance when T. cruzi epimastigotes were
incubated with 20 mM Bzn over six hours, we collected additional
metabolomics data using a higher concentration of Bzn, to allow
the detection of additional signals arising from Bzn derived
molecules and to observe effects on endogenous metabolites. For
this purpose, parasites were treated with 50 mM Bzn over 6 h in
the same general conditions (cBzt samples). Parasites that were not
exposed to Bzn (cBec) and parasites to which Bzn was added just
prior to the extraction of metabolites (cBzc) were used as controls.
Fifty percent (50%) of the parasites remained viable after this
treatment compared to untreated controls (not shown).
After data filtering, and analogous to the 20 mM Bzn treatment,
we observed several endogenous metabolites that showed signif-
icant differences between treated and control samples (File S2).
Consistent with the lower Bzn dose, trypanothione and homo-
trypanothione showed diminished levels after drug exposure,
probably a consequence of the formation of the drug-thiol
conjugates. Three lipids putatively identified as vitamin D-related
sterols showed diminished levels after treatment, whereas two
long-chain acyl-carnitines showed augmented levels, along with
the dipeptide c-glutamylcysteine (T-test P values,0.05 and FC.
2).
Treatment with 50 mM Bzn induced the appearance of a high
number of Bzn related signals, with 124 ions included in the
filtered data. After careful removal of LC-MS artefact ions, 36 of
these Bzn-specific peaks were listed as putative Bzn metabolites
(Table 2), although some of the analysed signals may still represent
in-source MS-derived fragments or adduct ions from true Bzn
metabolites. The raw data was scanned for putative Bzn
metabolites contained in the Bznmet database, and 14 additional
ions were retrieved (Table 2).
The Bzn metabolites identified using 20 mM Bzn were also
found in the 50 mM assay, with the exception of a metabolite with
m/zc 356.80 (16). An additional signal at m/zc 164.09 (RT
13.6 min) was found and attributed to 2-amino-N-benzylaceta-
mide (22). This compound was described as one of the products of
the in vitro enzymatic conversion of Bzn by NTRI [17]. The
metabolite with m/zc 246.11 was found in both positive and
negative ESI modes and with two different retention times (12 and
13.5 min) (11, 19). These could represent both the Bzn
hydroxylamine and/or hydroxy metabolites. Also, a conjugate of
reduced Bzn with c-glutamylcysteine was detected in 50 mM Bzn
treated samples (m/zc 478.16 and m/zc 239.08, RT 17.5 and
18.3 min) (20, 31). The signal at m/zc 393.17 (RT 32.4 min) was
assigned to a molecule composed of trypanothione linked to two
reduced Bzn molecules (41). A triple and a quadruple charged ion
were both attributed to a conjugate of reduced Bzn with a mixed
disulphide of trypanothione and glutathione (m/zc 418.82 and m/
zc 314.12 at RT 30.3 min) (29). The remaining adducts included
mercaptohistidine (35), an intermediate in ovothiol A synthesis,
and non-sulphur containing metabolites including valine (36) and
pyroglutamic acid (27). Some of the proposed structures were
supported by MSMS data, although fragmentation patterns could
not be obtained for all metabolites due to low abundance (File S4).
Figure 4 depicts proposed structures for some of the Bzn
metabolites detected in 20 mM and/or 50 mM Bzn metabolomics
analysis.
Many of the in situ detected Bzn-thiol conjugates display two
different but close retention times, which likely correspond to
structures equivalent to the ones described for reduced misonida-
zole adducts with glutathione [25]. These structures include the
thiol moiety bound to the imidazole ring through either carbons at
position 4 or position 5 (see Figure 4 for proposed structures). As an
example, Bzn-glutathione adduct chromatograms, and MS and
MSMS spectra are shown in Figure 5. Similar intensities were
observed at the two different retention times where Bzn-glutathione
adducts were detected, whereas Bzn-ovothiol A and Bzn-glutathio-
nylspermidine adducts displayed very low intensity peaks at one of
the retention times, which possibly results from preferred binding to
one of the two imidazole carbons (4-C or 5-C).
Discussion
Here we subject Trypanosoma cruzi to a HILIC chromatography
coupled to high accuracy MS platform, which has been
successfully used to analyse the cellular metabolomes of other
trypanosomatids [34,35,36,37]. This platform identified many
different small molecules, including low abundance metabolites,
and allowed their quantitative comparison. Medium composition
[38], extraction method [21] and the analytical platform used for
analysis [39] all influence output, and hence a standardized
protocol for trypanosomatid metabolomics was applied. To
minimize changes due to sample handling (that can provoke cell
leakage and metabolite draining), parasite pellets were not washed
before metabolite extraction, and hence medium samples were
always included as controls.
Amino acids and their derivatives (peptides, thiols and
polyamines) were the most abundant class identified, representing
56.7% of all detected metabolites. The high rate of endocytosis
and proteolytic activity [40], combined with high protein and
peptide content of culture medium probably explains this
abundance. We also identified and semi-quantitatively analysed
nearly one thousand compounds, including a wide array of
hydrophobic and hydrophilic molecules including many lipids,
carbohydrates and nucleotides among others. In spite of the
HILIC based platform used here being sub-optimal for very
lipophilic or highly acidic or poly-phosphorylated molecules, it is
clearly a relatively straight forward means for the systematic
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analysis of the metabolic state of Trypanosoma cruzi suitable for
studying many aspects of the biochemistry and pharmacology of
these parasites. Improvements in chromatography, such as the
introduction of pHILIC columns that can be operated at high pH
and thus improve resolution of phosphorylated compounds and
carboxylic acids could further improve coverage of the metabolome
[39].
Benznidazole is the drug of choice for treatment of both acute
and chronic Chagas disease. It has been widely agreed that Bzn
exerts activity through induction of reductive stress, involving
covalent modification of cellular macromolecules by intracellular
reduced metabolites of the parent compound [12,13]. Bzn can
arrest protein, RNA and DNA synthesis, as well as promote
damage to both nuclear and kinetoplast DNA and macromolecule
degradation [41,42,43,44]. Here we used 20 mM and 50 mM over
a 6 h incubation period with parasites to detect induced changes.
A recent report shows that DNA damage, including double strand
breaks, was found in T. cruzi after treatment with 240 mM Bzn for
up to 72 h [44]. 8-oxoguanine was encountered in T. cruzi DNA
after Bzn exposure and augmented levels of oxidized deoxygua-
nosine triphosphate (8-oxodGTP) are proposed as the main cause
for the observed DNA damage. Here we failed to identify key
oxidation products of cellular nucleotides, although using lower
drug concentrations for lower exposure times might be responsible
for this difference.
A type I nitroreductase (NTRI) has been shown to play a major
role in the cytotoxicity of both Bzn and Nfx, and diminished
NTRI activity correlates with nitroheterocycle cross resistance
[14,15]. Hall and Wilkinson (2012) studied the products of Bzn
reduction catalysed by T. brucei and T. cruzi NTRI in a cell-free
Figure 4. Bzn-derived metabolites. A number of Bzn derived molecules detected after treatment of T. cruzi epimastigotes with 20 mM and/or
50 mM Bzn are represented. A putative pathway for their in vivo formation is shown; double arrows indicate the existence of possible intermediates
such as nitroso or nitrenium derivatives. The observed m/z values corrected for proton gain or loss (observed m/z 6 1.007276) are included. Cys, G,
Ov, cGC, T and Gsp refer to cysteine, glutathione, ovothiol A, gamma-glutamylcysteine, trypanothione and glutathionylspermidine respectively. All
thiols are represented with their functional -S- groups separately. Bold numbers in parenthesis are the metabolite reference numbers (Tables 1 and 2).
doi:10.1371/journal.pntd.0002844.g004
Benznidazole Metabolism in Trypanosoma cruzi
PLOS Neglected Tropical Diseases | www.plosntds.org 10 May 2014 | Volume 8 | Issue 5 | e2844
Figure 5. Identification of Bzn-glutathione adducts. A. Upper plot is a chromatogram obtained from a sample of Bzn treated parasites
corresponding to m/z 536.1922 within a 3 ppm mass range (single-charged ion). Middle and bottom plots are magnified mass spectra in the regions
of interest within RT 18.5–19. B. Chromatograms and m/z plots corresponding to m/z 268.5997 (di-charged ion) in a sample of Bzn treated parasites.
In both A and B each ion is detected in two different but closely eluting chromatographic peaks with retention times centred at 17.8 and
18.6 minutes. Ionization charge states of the molecules are confirmed by the m/z difference for the isotopic 13C peaks, which are expected to be
1.0034 for mono charged ions and 0.5017 for di-charged ions (bottom plots). 34S isotopic peaks are also observed for both ions which are expected at
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system. Two consecutive two-electron reductions proceed with no
oxygen consumption, and lead to the formation of a hydroxyl-
amine derivative that then rearranges to form a dihydroxy-dihydro
derivative. This metabolite can decompose to give glyoxal, a well-
known toxic metabolite, postulated to contribute to the pleiotropic
effects that Bzn induces in trypanosomes [17]. However, the
biotransformation of Bzn in T. cruzi has not been directly
investigated, and was addressed in this metabolomic study.
If Bzn-related glyoxal damage occurs in T. cruzi, covalent
conjugates of glyoxal with small cellular molecules would be
expected to arise after Bzn treatment. However, we could not
detect signals belonging to the most common products of glyoxal
conjugation with any measured cellular metabolites including
nucleotides, nitrogenated bases or amino acids. The raw data was
scanned for low intensity signals but also failed to detect any
candidate glyoxal adducts. Deoxy-guanosine or guanosine ad-
ducts, the major adducts of glyoxal and methyl-glyoxal in vivo [45]
were not found. Likewise, carboxy-methyl-cysteine, which is
considered a marker for glyoxal cell damage in mammals [46],
was not detected. Possible roles for the trypanothione-dependent
glyoxalase system operative in T. cruzi [47] in detoxifying glyoxal
can be considered, although trypanothione-glyoxal conjugates
were not evident in the metabolomics data. It remains possible that
glyoxal conjugation to cellular macromolecules, not detected in the
small molecule population we measure, is associated with activity.
An ion corresponding to N-benzyl-2-guanidinoacetamide (5) (m/z
206.12 RT 11.7 min) was detected. This molecule is expected to
be formed as a consequence of glyoxal release from the dihydroxy-
dihydro derivative of Bzn. However, the relative intensity of this
ion (5) was an order of magnitude lower than the dihydroxy-
dihydro derivative (3), and 100-fold lower than the reduced amine
derivative (1). Whilst absolute quantification of Bzn metabolites
was not performed (due to a lack of authentic standards), this low
abundance strongly suggests that glyoxal production is not the
major route of Bzn metabolism in T. cruzi. The equilibrium
transfer of glyoxal from reduced Bzn reported in both in vitro
analyses was slow and inefficient [17,32]. Also, the covalent
interactions of Bzn with lipids, nucleic acids and proteins that have
been reported up to now were measured using 2 -14C labeled Bzn
[12] and thus do not include possible adducts arising from glyoxal
conjugation as this involves only carbons at position 4 and 5 of the
imidazole ring. Altogether, if glyoxal molecules are released in vivo
after Bzn reduction by T. cruzi, their fate remains uncertain.
Our metabolomics analysis revealed that Bzn stimulated
relatively few changes to metabolite concentrations within T. cruzi
in the conditions tested. These included diminished abundance of
the low molecular weight thiols trypanothione, homotrypa-
nothione and cysteine. Although these metabolic changes may
result from inhibition of enzymes involved in the biosynthesis of
these thiols; it is more likely that the perturbations are due to direct
thiol depletion by adduct formation. The major class of
metabolites to increase in abundance were glutamyl dipeptides,
suggesting upregulation of the c-glutamyl cycle involved in
glutathione recycling, which may result from turnover of Bzn-
glutathione and Bzn-trypanothione adducts. These results indicate
that the major metabolic perturbation of Bzn was detected in the
glutathione (and trypanothione) pathway. Additional metabolic
perturbations were observed following high-dose Bzn treatment,
including accumulation of long-chain acyl-carnitines and depletion
of some sterols. The role of these lipid perturbations in the
mechanism of Bzn activity is not known, although it is noted that
lipid, and especially sterol metabolism is already a validated drug
target for T. cruzi [48]. Interestingly, the ergosterol biosynthesis
inhibitor, posaconazole, exhibited synergistic activity when
administered with Bzn in a T. cruzi mouse model [49], potentially
supporting a link between Bzn action and sterol metabolism.The
putatively identified acyl-carnitines have not been previously
reported in T. cruzi and further investigation of the novel
trypanosomatid biochemistry discovered here may provide new
opportunities for drug target discovery for Chagas disease.
In addition to endogenous metabolites, a high number of novel
molecules, all drug derived metabolites, were detected in parasites
treated with Bzn. We were able to assign structures to some of
these molecules. Many represented reduced Bzn derivatives
previously detected using in vitro systems. For instance, a molecule
with a mass of 264 Da previously assigned to a dihydroxy-dihydro
derivative was detected (3). This molecule, 2-(2-amino-4,5-
dihydroxy-4,5-dihydroimidazol-1-yl)-N-benzylacetamide, was first
described as the main product of Bzn following chemical,
radiochemical or electrochemical reduction [32]. The nitroreduc-
tase NTRI reduces Bzn in vitro in the presence of NADH to a
number of products, including the dihydroxy-dihydro derivative as
the major product [17]. The MSMS fragmentation pattern of the
ion obtained from our T. cruzi samples (m/z 264.12, RT 13 min)
(3) is equivalent to the fragmentation pattern obtained for the in
vitro product of trypanosomal NTRI. Other metabolites obtained
after Bzn NTRI catalyzed reduction are the hydroxy and
hydroxylamine derivatives (11, 19), N-benzyl-2-guanidinoaceta-
mide (5) and 2-amino-N-benzylacetamide (22), which may arise
after reductive fragmentation as reported with misonidazole [50].
Ions corresponding to all of these molecules were detected in our
Bzn-treated parasites. High intensities of these metabolites in Bzn
treated parasites supports the hypothesis of a major contribution of
TcNTRI in the reduction and toxicity of Bzn towards T. cruzi.
Covalent adducts of reduced Bzn metabolites with the principal
low molecular weight thiols were prominent. Cysteine, glutathi-
one, c-glutamylcysteine, glutathionylspermidine, trypanothione
and Ovothiol A adducts were all detected, consistent with the
loss of free-thiols following Bzn and Nfx treatment of different
stages of T. cruzi [51,52,53]. Buthionine sulfoximine (BSO), an
inhibitor of glutathione synthesis, showed synergistic effects upon
co-administration with Nfx in a murine model [54] and a
correlation of the intracellular thiol concentration in different
strains and the toxicity of these compounds was also suggested
[51]. Here, we demonstrate the intracellular generation of Bzn-
thiol conjugates, and the accompanying depletion of endogenous
thiols, as major factors associated with drug action in T. cruzi
(Figures 4 and 5).
The relative roles of enzymatic (e.g. through glutathione and
trypanothione-S-transferases) and non-enzymatic production of
these thiol conjugates is not certain, but non-enzymatic conjuga-
tion to macromolecular thiols, e.g., cysteine in proteins, is also
likely to contribute to the mode of action of the drug as has been
reported for metronidazole and other nitroimidazoles [55,56].
Low molecular weight cysteine-rich proteins in T. cruzi were
shown to have these residues blocked when exposed to Nfx or Bzn,
1.9959 m/z difference for mono-charged ions and 0.9979 for di-charged ions. C. MSMS fragmentation spectrum for precursor ion m/z 536.19. The m/
zc =m/z21.007276 (proton mass). The proposed structures for the precursor ion (Bzn-glutathione adduct) and for some of the most intense
fragments are shown. Exact theoretical mass and formula are included together with each fragment structure. A 4-C adduct is depicted though a 5-C
adduct could be represented.
doi:10.1371/journal.pntd.0002844.g005
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again indicating binding of metabolites from these drugs to
macromolecular cysteine residues [57]. Many enzymes rely
on active cysteine residues to exert their functions including the
tryparedoxin peroxidase-tryparedoxin system, among others, and
could be targeted by Bzn metabolites [58]. Interestingly, however,
our metabolite profiling of treated cells indicated relatively little
change to cellular metabolism which suggests that most cellular
enzymes have not been affected sufficiently to change the flux
through most metabolic pathways. Also, some of the observed Bzn-
derived metabolites included covalent adducts with small metabolites
other than thiols including pyroglutamic acid adducts and possibly
valine adducts. This pleiotropic reactivity of Bzn derived metabolites
could also account for some of its toxicity and for the binding of Bzn
to other macromolecules including lipids and nucleic acids.
In addition to the Bzn-derivatives previously noted as NTRI
products, other metabolites were also found in our analysis.
Among these, 2-(2-amino-1H-imidazol-1-yl)-N-benzylacetamide
(1) has one of the most intense signals detected. This molecule
arises after a six electron reduction of Bzn and was only detected in
a low yield after zinc chemical reduction of Bzn, and was not
detected after radiation or electrochemical reduction [32]. The
molecule was, however, detected after Bzn metabolism by
mammalian tissues, for which NADPH–cytochrome P450 reduc-
tases and cytochrome P450 may be responsible. As a stable
molecule it is proposed to be non-toxic [59]. Interestingly,
overexpression of a NADPH–cytochrome P450 reductase
(TcCPR-B) in T. cruzi epimastigotes decreased sensitivity to Nfx
and Bzn [60]. A role of TcCPR-B in the detoxification of Bzn was
therefore suggested but the mechanism remains unclear, and
reduction to an amine non-toxic product could explain the
observed phenotype. The methoxy derivatives of the dihydroxy-
dihydro form of Bzn may also represent detoxification products.
Other enzymes might also have roles in the generation of the
reduced Bzn metabolites, such as the two structurally related
enzymes TcOYE [61,62] and TcAKR, which binds in vitro to
immobilized Bzn (Trochine A., Faral-Tello P. and Robello C.
unpublished data). As T. cruzi shows differences in pathogenicity,
virulence, transmissibility and drug sensitivity through its six major
genotypic divergent lineages [63], the complex pattern of Bzn
metabolism that we have unravelled here could help explain the
significant variability in sensitivity to this drug in the different
parasite-isolates across Latin America [64,65]. Investigation of the
enzymes responsible for the formation of each of the Bzn
metabolites and its possible implications on Bzn toxicity or
resistance should be straightforward using the metabolomics
platform and data obtained in this work, together with overex-
pressing or knock-out parasite lines.
Conclusions
Metabolomics technology has allowed us to gain further insight
into Bzn mechanism of action. The MS based metabolomics
analysis is a powerful tool and can be used to analyse the mode of
action of different types of drugs in Trypanosoma cruzi. These in turn
should help us understand resistance mechanisms as well as the
natural variation in T. cruzi susceptibility to nitroheterocycles and
to improve available and future drugs. Through this work we have
shown that Bzn is extensively metabolized to a number of molecules
once it enters T. cruzi. These molecules include reduction products
and covalent adducts with low molecular weight thiols and other
small molecules. In addition, the metabolomics analysis of
endogenous metabolites identified low molecular weight thiol
depletion and turnover as the major metabolic impact of Bzn
treatment. We here propose that the covalent binding of Bzn with
lowmolecular weight thiols as well as with protein thiols is a primary
cause of the drug’s toxicity against T. cruzi.
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Figure S1 Principal Components Analysis plot. PCA
Score Plots were generated with normalized MS peak intensity
data using Metaboanalyst [68,69]. PCA is an unsupervised
clustering or classification method which projects complex high-
dimensional data to a new coordinate system with fewer
dimensions. The projection direction is calculated to maximize
the data variance in just the first few dimensions, called principal
components (PC). Scores represent the original data in the new
coordinate system and are weighted average of the original
variables. Samples: Med: fresh medium, cBc: control of non-
treated parasites (20 mM Bzn added before metabolite extraction),
cBt: 20 mM Bzn treated parasites, cTc: control of non-treated
parasites, mBc: cBc spent medium, mBt: cBt spent medium.
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